Other Barks & Bites for Friday, May 1: EU Lands on USTR’s Special 301 Watch List; Battery Recycling Patent Families Increase Seven-Fold in Past Decade; and Google Cert Petition Challenges Settled Expectations Doctrine

This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European Union as a Watch List nation for IP-related issues; Senators Dick Durbin (D-IL) and Maria Cantwell (D-WA) publicly oppose the Trump Administration’s decisions to cut federal funding for science and upend the National Science Board; and more.

UNC Charlotte Highlights the Power of Invention at 2026 Invention of the Year Awards

The University of North Carolina at Charlotte brought together leaders from government, academia, industry, and the defense community for its 2026 Invention of the Year Awards, an evening that showcased the university’s growing role as a national engine of innovation, commercialization, and technological impact.

The Latest Attempt to Expose SAWS Highlights Structural Flaws at the USPTO

Whether or not the United States Patent and Trademark Office (USPTO) wants to admit it, over most of the last generation there has been a secret examination docket. Not surprisingly, such a secret examination docket is strictly prohibited by federal law. A newly filed joint status report in Morinville v. USPTO brings this issue to the fore and underscores the lack of transparency and accountability of secret internal patent review programs at the USPTO. Procedurally, the latest filing seeks to expose the USPTO shadow docket through a new round of discovery, which is currently being considered by the United States District Court for the District of Columbia.

Hot Takes: What the Oral Arguments in Hikma/ Amarin Revealed

The Supreme Court heard oral arguments yesterday in Hikma Pharmaceuticals USA v. Amarin Pharma, Inc., a case with broad implications for the generic industry’s practice of “skinny labeling” and the induced infringement standard for patent law and beyond. IPWatchdog reached out to members of the IP community for their initial takeaways from yesterday’s arguments.

Federal Circuit Vacates PTAB Obviousness Determination and Holds Real Party in Interest Challenge Unreviewable

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Wednesday in Federal Express Corporation v. Qualcomm Incorporated, vacating a determination by the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) that certain claims of a Federal Express Corporation patent were unpatentable as obvious. The CAFC also held that it could not review the PTAB’s refusal to determine whether all real parties in interest were identified in the petition for inter partes review (IPR).

Thompson Patent Law is Seeking an Associate Patent Attorney

A full-time, fully remote role is available at Thompson Patent Law (TPL) for an experienced Associate Patent Attorney. TPL understands that many attorneys are looking for more – a greater challenge, consistent workflow, a meaningful culture, and real opportunities to grow – and offers a steady flow of high-quality patent work, a full-time remote role supported by strong systems, a respectful, values-driven culture, and direct mentorship from Craige Thompson, JD, MBA, EE, PE, Managing Principal Patent Attorney and #1 Amazon best-selling author of Patent Offense.

Justices Voice Concern that Upholding CAFC’s Hikma ‘Skinny Label’ Ruling Will Harm Generics Industry

The U.S. Supreme Court heard oral arguments today in Hikma v. Amarin, a closely-watched case that in part asks the Justices to weigh in on whether a drugmaker calling its product a “generic version” while citing public sales information about the branded drug induces infringement of a patented use fully carved out by the generic’s label. Hikma’s petition also asks whether a complaint states an induced infringement claim if it fails to allege any instruction or statement by the defendant mentioning the patented use. While some Justices today questioned why the case was even before them, others seemed concerned about the potential impact of the case for the generic pharmaceutical industry.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates